Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID lung damage lingers months later, new study reveals

NCT ID NCT04422613

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 73 people who were hospitalized with severe COVID-19 pneumonia to see if their lungs still had problems 4 months later. The main focus was on how well oxygen moves from the lungs into the blood. The goal was to better understand these lasting issues so doctors can help patients recover more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

73 people

The number who actually took part.

Started

May 2020

Finished

Oct 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with COVID-19 pneumonia * Positive PCR for COVID-19 on respiratory sample (saliva, nasopharyngeal, bronchial, tracheal aspiration or LBA) * Having required hospitalization in the pulmonology service, intensive care in pneumology or resuscitation service at the Toulouse University Hospital * Saturation \<94% in ambient air at diagnosis * Patient having a chest CT-scan proving pneumonia during his hospitalization * Patient ≥ 18 years old * Patient who has given written consent to participate in the study Exclusion Criteria: * Patient hospitalized for pneumonia not documented by a chest CT-scan * Patient with negative COVID PCR * Patient known before the episode of COVID-19 pneumonia for a respiratory or cardiac pathology which can lead in itself to an alteration of gas exchanges * Patient under curators / guardianship * Pregnant patient * Minor patient * Absence of consent for participation in the study * Medical condition that does not allow for pulmonary function test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia, viral are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult acute respiratory distress syndrome COVID-19 pulmonary embolism viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia, viral

Contacts and locations

Locations

  • University Hospital of Toulouse

    Toulouse, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.